San Francisco Bay Area
I am passionate to bringing effective therapies to cancer patients. As a physician trained in oncology as well as skilled in commercialization strategy, I am uniquely qualified to change the paradigm of cancer care and enable physicians and payors to provide the best medical care possible. In the past 10 years, my teams have launched 5 new products, guided the expansion of the oncology portfolio and partnered with several of the Top 20 pharma companies. I thrive in tackling complex challenges within a fast moving environment where I can build and nurture successful and accountable teams.
Leading a world class team of development experts to bring new cell therapies to patients suffering from life threatening diseases.
Building and leading the development organization to develop the first-in-class CD94 antibody in T-cell lymphomas and auto-immune diseases and the myeloid cell engaging bispecifics for vairous tumor types.
Led the clinical development of the first in class allogeneic CRISPR gene edited CAR T cell program targeting CD70 in T cell lymphomas and RCC as well as the partnered gene engineered NK cell program.
Led a team of MDs and clinical scientist to file 4 INDS and develop drugs to mid-stage clinical development, stand-alone as well as pharma partnered programs
Preparing our first-in-human study for CytomX proprietary Probody platform, proteins such as antibodies cleaved by proteases only active in the tumor microenvironment.
Supported the approval of the first Pi3K inhibitor and development of additional indications.